Canada Markets close in 4 hrs 11 mins

Nuvo Pharmaceuticals Inc. (MRVFF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.62200.0000 (0.00%)
As of 01:56PM EDT. Market open.
Full screen
Loading interactive chart...
  • Business Wire

    Miravo Healthcare™ Announces Director Election Results of its Annual Meeting of Shareholders

    MISSISSAUGA, Ontario, May 16, 2022--Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company) a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced that at its 2022 Virtual Annual Meeting of Shareholders held on May 16, 2022 (the Meeting), all nominees listed in the management proxy circular dated April 8, 2022 were elected as directors of the Company.

  • Business Wire

    Miravo Healthcare™ Announces First Quarter 2022 Results

    MISSISSAUGA, Ontario, May 16, 2022--Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced its financial and operational results for the three months ended March 31, 2022. For further details on the results, please refer to Miravo’s Management, Discussion and Analysis (MD&A) and Condensed Consolidated Interim Financial Statements f

  • Business Wire

    Miravo Healthcare™ Provides an Update on the United States Pennsaid® 2% Business

    MISSISSAUGA, Ontario, May 12, 2022--Nuvo Pharmaceuticals Inc. (TSX:MRV; OTCQX:MRVFF) d/b/a Miravo Healthcare (Miravo or the Company), a Canadian-focused healthcare company with global reach and a diversified portfolio of commercial products, today announced that it has become aware that the United States’ Food & Drug Administration (FDA) approved Apotex Inc.’s abbreviated new drug application for a generic version of Pennsaid 2% on May 6, 2022. Miravo’s partner in the United States owns the Penn